Iyo Mayu, Kawasaki Hiroaki, Taira Kazunari
Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Japan.
Methods Mol Biol. 2004;252:257-65. doi: 10.1385/1-59259-746-7:257.
Ribozymes are small and versatile nucleic acids that can cleave RNAs at specific sites. These molecules have great potential to be used as effective gene-therapeutic agents. However, because of the limitation for cleavable sequences within the target mRNA, in some cases conventional ribozymes have failed to exhibit precise cleavage specificity. A maxizyme is the dimer of minimized ribozymes (minizymes), which can specifically cleave two distinct target sites. The maxizyme also has an allosteric function in that it can form an active conformation and cleave the two target sites only when it recognizes two distinct target sites. We demonstrated previously that an allosterically controllable maxizyme was a powerful tool in the disruption of an abnormal chimeric RNA (bcr-abl) in cells and in mice. Furthermore, more than five custom-designed maxizymes have clearly demonstrated these allosteric functions in vitro and in vivo. Thus, maxizyme technology is not limited to one specific case, but may have broad general applicability in molecular biology and in molecular gene therapy.
核酶是一类小而多功能的核酸,能够在特定位点切割RNA。这些分子具有作为有效基因治疗剂的巨大潜力。然而,由于靶mRNA内可切割序列的限制,在某些情况下,传统核酶未能表现出精确的切割特异性。最大核酶是最小化核酶(微型核酶)的二聚体,它可以特异性切割两个不同的靶位点。最大核酶还具有变构功能,即它可以形成活性构象,并且仅在识别两个不同的靶位点时才切割这两个靶位点。我们之前证明,变构可控的最大核酶是破坏细胞和小鼠中异常嵌合RNA(bcr-abl)的有力工具。此外,超过五种定制设计的最大核酶已在体外和体内清楚地证明了这些变构功能。因此,最大核酶技术不仅限于一种特定情况,而是可能在分子生物学和分子基因治疗中具有广泛的普遍适用性。